Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia

WEE1 is a cell cycle and DNA damage response kinase that is emerging as a therapeutic target for cancer. AZD1775 is a small molecule inhibitor of WEE1, currently in early phase clinical trials as a single agent and in combination with more conventional anti-neoplastic agents. As resistance to kinase...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Garcia, Tamara B., Uluisik, Rizvan C., van Linden, Annemie A., Jones, Kenneth L., Venkataraman, Sujatha, Vibhakar, Rajeev, Porter, Christopher C.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066074/
https://ncbi.nlm.nih.gov/pubmed/32195191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00296
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars